Timothy Wilens, one of the psychiatrists at Mass General investigated by Senator Charles Grassley for pocketing and not reporting income from drug companies is STILL taking money from pharma.*Added note: it appears Thomas Spencer is also still taking money from pharma: $5,000 from Eli Lilly . Something stinks at Mass General!
Dr. Timothy Wilens is in the ProPublica Dollars for Docs database. Clearly, the investigation from Grassley did nothing to change the way Wilens does business.
Dollars for Docs:
ELI LILLY, makers of Zyprexa, Prozac
Payee TIMOTHY WILENS
Listed Name WILENS, TIMOTHY E.
City WINCHESTER
State MA
Number of activities 2
Patient Education Programs 0.00
Healthcare Professional Education Programs 0.00
Advising/Consulting and International Education Programs 9250.00
Total 9250.00
---
Boston .com June 2008
"Three Harvard psychiatrists facing a US Senate inquiry got a vote of confidence from their hospital as "beloved and trusted by thousands of grateful children and families." Senator Charles Grassley is looking into the doctors' failure to report payments of more than a million dollars in consulting fees from drug makers from 2000 to 2007.
A memo from top officials at Massachusetts General Hospital obtained by the Globe praised Drs. Joseph Biederman, Timothy Wilens, and Thomas Spencer as "pioneers in the field of child mental health" while also endorsing "closely managed" collaboration with industry and promising a review of conflict-of-interest policies.
AND
"Our ultimate hope is that after such a comprehensive review, our processes will be further enhanced, strengthened and streamlined. We will no doubt learn a great deal from this experience – as difficult as it may be – and we must be willing to share the insights and perspectives we gain to improve conflict-of-interest processes not just here, but at academic institutions nationwide.
Peter L. Slavin, MD, President, MGHDavid F. Torchiana, MD, Chairman and CEO, MGPO"-June 2008
Do you think they learned from it yet?
Subscribe to:
Post Comments (Atom)
Posts
0 comments:
Post a Comment